NICE draft guidance recommends finerenone for type of chronic heart failure
NICE has issued final draft guidance recommending the use of finerenone for adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. The drug is presented as a potential alternative to spironolactone, offering a different side-effect profile for patients.
Why it matters
This recommendation could expand treatment options for up to 280,000 patients in England suffering from chronic heart failure.
Up to 280,000 people in England could be eligible for a new drug to treat heart failure with preserved or mildly reduced ejection fraction, the National Institute for Health and Care Excellence (NICE) has said.
In final draft guidance published on 15 July 2026, NICE recommended that finerenone (Kerendia; Bayer) could be used — within its marketing authorisation — as an option to treat symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults.
The drug is a mineralocorticoid receptor antagonist (MRA), which should be considered alongside an angiotensin-converting enzyme inhibitor, a beta-blocker and a sodium-glucose cotransporter-2 (SGLT2) inhibitor for treating heart failure with mildly reduced ejection fraction, the draft guidance said.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in